Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Clinical Trials Business Strategies Companies

F2G Plans Orphan Drug Strategy With Novel Antifungal

  • Analysis

Executive Summary

Olorofim employs a novel mechanism of action within the antifungal space and was tested in patients with high mortality risk who had exhausted treatment options.

You may also be interested in...



Scynexis Switches Focus To Hospital Indications For Ibrexafungerp

With sluggish sales so far for antifungal Brexafemme, approved for vulvovaginal candidiasis, Scynexis will look to out-license the product and cut staff.

F2G Tops Up Funds For Launch Of New Class Of Antifungal

Having banked a $100m upfront fee from licensing partner Shionogi a couple of months ago, F2G has now unveiled a $70m financing to advance its late-stage novel oral antifungal, olorofim.

Asia Deal Watch: Astellas, GO Team Up On Targeted Cancer Therapy

Astellas subsidiary Xyphos will partner with GO to discover novel antibodies against two glycoprotein targets. SciNeuro picks up abandoned GSK programs in cardiovascular medicine for potential use in the neurodegeneration space.

Table

View full table

Topics

Related Companies

Tags:
Clinical Trials Business Strategies Companies
Latest Headlines

Podcast: Diversity, Equity, and Inclusion Measures Continue to Evolve in the Clinical Space

Eisai/Biogen’s Leqembi Breezes Through Adcomm; Labeling Discussions With US FDA May Be Knottier

Disc Sees Promise In Hematology With Former Roche Schizophrenia Candidate

Gilead’s Kite Hopes To Reinforce Commercial CAR-T Lead With Yescarta Data

See All
UsernamePublicRestriction

Register

SC147269

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By